Investment analysts at Credit Suisse Group started coverage on shares of Sartorius Stedim Biotech (OTCMKTS:SDMHF – Get Rating) in a report released on Monday, The Fly reports. The firm set a “neutral” rating on the stock.
Separately, Morgan Stanley dropped their target price on Sartorius Stedim Biotech from €465.00 ($505.43) to €455.00 ($494.57) in a report on Tuesday, October 11th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Sartorius Stedim Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $448.33.
Sartorius Stedim Biotech Price Performance
Sartorius Stedim Biotech stock opened at $348.00 on Monday. The business’s fifty day simple moving average is $326.59 and its two-hundred day simple moving average is $330.80. Sartorius Stedim Biotech has a 12 month low of $282.50 and a 12 month high of $447.00.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech SA produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.
- Get a free copy of the StockNews.com research report on Sartorius Stedim Biotech (SDMHF)
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
Receive News & Ratings for Sartorius Stedim Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Stedim Biotech and related companies with MarketBeat.com's FREE daily email newsletter.